![REXULTI user Kimberly with Major Depressive Disorder picnicking. REXULTI user Kimberly with Major Depressive Disorder picnicking.](/sites/g/files/qhldwo8606/files/styles/max_2048/public/2023-07/hero-mdd-desktop.jpg?itok=jHVe-xEW)
For adult patients with
MDD on an ADT, Add REXULTI® (brexpiprazole) for antidepressant symptom response
A 6-week, double-blind, placebo-controlled, fixed-dose pivotal trial studied mean change from baseline (SE) in MÅDRS total score at 6 weeks (-8.4 [0.6] for ADT + REXULTI [n=175] vs -5.2 [0.6] for ADT + placebo [n=178], p=0.0002 for 2 mg/day recommended dose) in adults with MDD.2
![REXULTI user Kimberly with Major Depressive Disorder picnicking. REXULTI user Kimberly with Major Depressive Disorder picnicking.](/sites/g/files/qhldwo8606/files/styles/max_1300x1300/public/2023-07/hero-mdd-mobile.jpg?itok=mP3ASqtw)
For adult patients with
MDD on an ADT, Add REXULTI® (brexpiprazole) for antidepressant symptom response
Actor portrayal. Not an actual patient.
A 6-week, double-blind, placebo-controlled, fixed-dose pivotal trial studied mean change from baseline (SE) in MÅDRS total score at 6 weeks (-8.4 [0.6] for ADT + REXULTI [n=175] vs -5.2 [0.6] for ADT + placebo [n=178], p=0.0002 for 2 mg/day recommended dose) in adults with MDD.2
Actor portrayal. Not an actual patient.